EUVIMEDEUVIMED entdecken
Open Access

Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A - and NPM1 -altered leukemias

Min Chul Kwon, Jan Willem Thuring, Olivier Querolle iD, Xuedong Dai, Tinne Verhulst, Vineet Pande, Ann Marien, Dries Goffin, Daniela V Wenge iD, Hong Yue iD, Jevon A Cutler iD, Cyrus Jin und 35 weitere

Blood · 12.09.2024 · 144 (11) · 1206-1220

DOI: 10.1182/blood.2023022480 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, erschienen am 12.09.2024. Verfasst von Min Chul Kwon und 46 weiteren Autor:innen. Beteiligte Einrichtung: Discovery Oncology, Janssen R&D, Beerse, Belgium. Hauptthemen laut MEDLINE: Nucleophosmin, Myeloid-Lymphoid Leukemia Protein, Histone-Lysine N-Methyltransferase, Nuclear Proteins. Die Arbeit wurde bisher 82-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The interaction between menin and histone-lysine N-methyltransferase 2A (KMT2A) is a critical dependency for KMT2A- or nucleophosmin 1 (NPM1)–altered leukemias and an emerging opportunity for therapeutic development. JNJ-75276617 (bleximenib) is a novel, orally bioavailable, potent, and selective protein-protein interaction inhibitor of the binding between menin and KMT2A. In KMT2A-rearranged (KMT2A-r) and NPM1-mutant (NPM1c) acute myeloid leukemia (AML) cells, JNJ-75276617 inhibited the association of the menin-KMT2A complex with chromatin at target gene promoters, resulting in reduced expression of several menin-KMT2A target genes, including MEIS1 and FLT3. JNJ-75276617 displayed potent antiproliferative activity across several AML and acute lymphoblastic leukemia (ALL) cell lines and patient samples harboring KMT2A or NPM1 alterations in vitro. In xenograft models of AML and ALL, JNJ-75276617 reduced leukemic burden and provided a significant dose-dependent survival benefit accompanied by expression changes of menin-KMT2A target genes. JNJ-75276617 demonstrated synergistic effects with gilteritinib in vitro in AML cells harboring KMT2A-r. JNJ-75276617 further exhibited synergistic effects with venetoclax and azacitidine in AML cells bearing KMT2A-r in vitro, and significantly increased survival in mice. Interestingly, JNJ-75276617 showed potent antiproliferative activity in cell lines engineered with recently discovered mutations (MEN1M327I or MEN1T349M) that developed in patients refractory to the menin-KMT2A inhibitor revumenib. A cocrystal structure of menin in complex with JNJ-75276617 indicates a unique binding mode distinct from other menin-KMT2A inhibitors, including revumenib. JNJ-75276617 is being clinically investigated for acute leukemias harboring KMT2A or NPM1 alterations, as a monotherapy for relapsed/refractory acute leukemia (NCT04811560), or in combination with AML-directed therapies (NCT05453903).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NucleophosminMyeloid-Lymphoid Leukemia ProteinHistone-Lysine N-MethyltransferaseNuclear ProteinsLeukemia, Myeloid, AcuteHumansAnimalsMiceXenograft Model Antitumor AssaysProto-Oncogene ProteinsCell Line, TumorCell ProliferationMice, SCIDPrecursor Cell Lymphoblastic Leukemia-LymphomaAntineoplastic Agents

Substanzen

NucleophosminNPM1 protein, humanMEN1 protein, humanKMT2A protein, humanMyeloid-Lymphoid Leukemia ProteinHistone-Lysine N-MethyltransferaseNuclear ProteinsNpm1 protein, mouseProto-Oncogene ProteinsAntineoplastic Agents

Autor:innen und Institutionen

  • Discovery Oncology, Janssen R&D, Beerse, Belgium.
  • Discovery Product Development and Supply, Janssen R&D, Beerse, Belgium.
  • Discovery Product Development and Supply, Janssen R&D, Shanghai, China.
  • Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Division of Hematology/Oncology, Boston Children's Hospital, and Harvard Medical School, Boston, MA.
  • Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.

ORCID-Profile: Olivier Querolle, Daniela V Wenge, Hong Yue, Jevon A Cutler, Florian Perner, Shanna M Hogeling, Frank Jacobs, Balpreet Bhogal, Robert Kirkpatrick, Ruth Steele, Christina Guttke, Eric S Fischer, Jan Jacob Schuringa

Förderung

  • NCI NIH HHS

Zitieren

APA

Kwon, M. C., Thuring, J. W., Querolle, O., Dai, X., Verhulst, T., Pande, V., Marien, A., Goffin, D., Wenge, D. V., Yue, H., Cutler, J. A., Jin, C., Perner, F., Hogeling, S. M., Shaffer, P. L., Jacobs, F., Vinken, P., Cai, W., Keersmaekers, V., …, & Philippar, U. (2024). Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A - and NPM1 -altered leukemias. Blood, 144(11), 1206-1220. https://doi.org/10.1182/blood.2023022480

Vancouver

Kwon MC, Thuring JW, Querolle O, Dai X, Verhulst T, Pande V, et al. Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A - and NPM1 -altered leukemias. Blood. 2024;144(11):1206-1220. doi:10.1182/blood.2023022480

BibTeX
@article{Kwon2024,
  author = {Kwon, Min Chul and Thuring, Jan Willem and Querolle, Olivier and Dai, Xuedong and Verhulst, Tinne and Pande, Vineet and Marien, Ann and Goffin, Dries and Wenge, Daniela V and Yue, Hong and Cutler, Jevon A and Jin, Cyrus and Perner, Florian and Hogeling, Shanna M and Shaffer, Paul L and Jacobs, Frank and Vinken, Petra and Cai, Wei and Keersmaekers, Vikki and Eyassu, Filmon and Bhogal, Balpreet and Verstraeten, Karin and El Ashkar, Sara and Perry, Jennifer A and Jayaguru, Prathiba and Barreyro, Laura and Kuchnio, Anna and Darville, Nicolas and Krosky, Daniel and Urbanietz, Gregor and Verbist, Bie and Edwards, James P and Cowley, Glenn S and Kirkpatrick, Robert and Steele, Ruth and Ferrante, Lucille and Guttke, Christina and Daskalakis, Nikki and Pietsch, E Christine and Wilson, David M and Attar, Ricardo and Elsayed, Yusri and Fischer, Eric S and Schuringa, Jan Jacob and Armstrong, Scott A and Packman, Kathryn and Philippar, Ulrike},
  title = {Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A - and NPM1 -altered leukemias},
  journal = {Blood},
  year = {2024},
  volume = {144},
  number = {11},
  pages = {1206--1220},
  doi = {10.1182/blood.2023022480}
}
Kostenlos starten →